Acceleron Pharma (XLRN) Misses Q4 EPS by 14c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. DAL
9. TMUS
10. VZ

Go back to Acceleron Pharma (XLRN) Misses Q4 EPS by 14c, Revenues Beat

Barclays Starts Acceleron Pharma (XLRN) at Overweight

February 27, 2020 6:57 AM EST

Barclays analyst Carter Gould initiates coverage on Acceleron Pharma (NASDAQ: XLRN) with a Overweight rating and a price target of $107.00.


For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.


Shares of Acceleron Pharma closed at $87.36 yesterday.

... More